Skip to main content
2024 CRT Conference Main banner
Back

C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School.
The institutes have led over 1,000 studies, published 5,500 manuscripts in the peer review literature (including 144 in the New England Journal) and have led 60 FDA submissions from their network of 7,000 sites worldwide. In 2014 and 2018 - 2020 Gibson was ranked as one of the world's most highly cited authors in all of science in the past decade by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 136,000 times, and he has an H index of 129 and an i10-index of 523.




Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Beren Therapeutics: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); BOEHRINGER INGELHEIM IT.SpA.: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); Esperion: Consultant (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Consultant (Ongoing), Shareholder (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); New Amsterdam Pharma: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Samsung: Consultant (Ongoing); SCAD Alliance: Consultant (Ongoing); SCAI: Consultant (Ongoing); SFJ: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

Presentation(s):